

# CITATION REPORT

List of articles citing

**Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial**

**DOI: 10.1016/s1665-2681(19)31539-x**  
**Annals of Hepatology, 2011, 10, 277-286.**

**Source:** <https://exaly.com/paper-pdf/50515985/citation-report.pdf>

**Version:** 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
140	Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic. <b>2011</b> , 22, 479-88		86
139	Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. <i>Hepatology</i> , <b>2012</b> , 56, 1291-9	11.2	112
138	Nonalcoholic fatty liver disease. <b>2012</b> , 16, 397-419		55
137	Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis. <i>Journal of Clinical and Experimental Hepatology</i> , <b>2012</b> , 2, 156-73	4.1	27
136	Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor- $\beta$ -lowering property. <b>2012</b> , 44, 492-6		45
135	Features, diagnosis, and treatment of nonalcoholic fatty liver disease. <b>2012</b> , 10, 837-58		182
134	Pathophysiology guided treatment of nonalcoholic steatohepatitis. <b>2012</b> , 27 Suppl 2, 58-64		23
133	Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. <i>Hepatology</i> , <b>2013</b> , 58, 1644-54	11.2	109
132	Non-alcoholic steatohepatitis: the role of oxidized low-density lipoproteins. <b>2013</b> , 58, 801-10		61
131	Nonalcoholic fatty liver disease: current and potential therapies. <i>Life Sciences</i> , <b>2013</b> , 92, 114-8	6.8	58
130	Pharmacologic therapy for nonalcoholic fatty liver disease in adults. <b>2013</b> , 33, 223-42		11
129	Nonalcoholic fatty liver disease: current issues and novel treatment approaches. <b>2013</b> , 73, 1-14		123
128	Involvement of free radicals and oxidative stress in NAFLD/NASH. <b>2013</b> , 47, 869-80		182
127	Immune therapy for nonalcoholic steatohepatitis: are we there yet?. <b>2013</b> , 47, 298-307		12
126	Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review. <b>2014</b> , 20, 12182-201		40
125	Non-alcoholic fatty liver disease: what the clinician needs to know. <b>2014</b> , 20, 12956-80		117
124	Pharmacologic Management of Non-Alcoholic Fatty Liver Disease. <b>2014</b> , 03,		1

123	Kupffer cells: increasingly significant role in nonalcoholic fatty liver disease. <i>Annals of Hepatology</i> , <b>2014</b> , 13, 489-495	3.1	68
122	Management of fatty liver disease with the metabolic syndrome. <b>2014</b> , 8, 487-500		21
121	Chemoprevention of nonalcoholic fatty liver disease by dietary natural compounds. <b>2014</b> , 58, 147-71		63
120	State of the art: treatment of nonalcoholic steatohepatitis. <b>2014</b> , 30, 223-37		18
119	Pentoxifylline for the treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized double-blind, placebo-controlled studies. <b>2014</b> , 26, 646-53		33
118	[Non-alcoholic fatty liver: position document of the Catalan Society of Gastroenterology]. <b>2014</b> , 37, 372-83		7
117	Are oxidative stress mechanisms the common denominator in the progression from hepatic steatosis towards non-alcoholic steatohepatitis (NASH)?. <b>2014</b> , 34, e180-90		73
116	Obesity and the liver: nonalcoholic fatty liver disease. <b>2014</b> , 164, 312-22		52
115	Review article: the management of paediatric nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 40, 1155-70	6.1	33
114	Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis. <i>Hepatology</i> , <b>2015</b> , 62, 1417-32	11.2	112
113	Treatment of nonalcoholic steatohepatitis in adults: present and future. <b>2015</b> , 2015, 732870		19
112	Drug-induced fatty liver disease: An overview of pathogenesis and management. <i>Annals of Hepatology</i> , <b>2015</b> , 14, 789-806	3.1	48
111	Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. <b>2015</b> , 21, 3777-85		82
110	Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. <b>2015</b> , 50, 364-77		138
109	Non-alcoholic fatty liver disease in 2015. <i>World Journal of Hepatology</i> , <b>2015</b> , 7, 1450-9	3.4	124
108	Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <b>2015</b> , 90, 1233-46		142
107	Endoplasmic reticulum stress and Oxidative stress in the pathogenesis of Non-alcoholic fatty liver disease. <b>2015</b> , 49, 1405-18		182
106	Management and diagnosis of fatty liver disease. <b>2015</b> , 9, 671-83		7

105	Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine. <b>2015</b> , 240, 809-20	67
104	Treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). <b>2015</b> , 292-305	1
103	Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. <b>2015</b> , 45, 363-77	122
102	Pharmacotherapy for Nonalcoholic Fatty Liver Disease. <b>2015</b> , 35, 338-48	21
101	Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. <b>2015</b> , 13, 643-54.e1-9; quiz e39-40	804
100	. <b>2016</b> ,	2
99	A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD. <b>2016</b> , 2016, 7109270	42
98	Effects of treatment of NAFLD on the metabolic syndrome. <b>2016</b> , 189-195	
97	Effects of pentoxifylline on inflammatory markers and blood pressure: a systematic review and meta-analysis of randomized controlled trials. <b>2016</b> , 34, 2318-2329	25
96	Pediatric Nonalcoholic Fatty Liver Disease: A Report from the Expert Committee on Nonalcoholic Fatty Liver Disease (ECON). <b>2016</b> , 172, 9-13	14
95	Future Treatments of NASH. <b>2016</b> , 15, 125-133	2
94	Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus. <b>2016</b> , 2, 9	35
93	Sinusoidal communication in liver fibrosis and regeneration. <b>2016</b> , 65, 608-17	159
92	Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. <b>2016</b> , 59, 1112-20	88
91	Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus. <b>2016</b> , 45, 765-781	79
90	Promising therapies for treatment of nonalcoholic steatohepatitis. <b>2016</b> , 21, 343-57	23
89	Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. <b>2016</b> , 1, 56-67	103
88	Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 1109-23	6.1 31

87	Targeting Hepatic Fibrosis in Autoimmune Hepatitis. <b>2016</b> , 61, 3118-3139	22
86	Should physicians be prescribing or patients self-medicating with orlistat, vitamin E, vitamin D, insulin sensitizers, pentoxifylline, or coffee?. <b>2016</b> , 182-188	
85	Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options. <b>2016</b> , 8, 75-84	19
84	Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis. <b>2016</b> , 95, e4529	39
83	Pharmacological management of nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , <b>2016</b> , 65, 1183-95	12.7 70
82	The Liver in Systemic Diseases. <b>2016</b> ,	1
81	The intersection of nonalcoholic fatty liver disease and obesity. <b>2016</b> , 8, 323rv1	43
80	Alcoholic and Non-Alcoholic Fatty Liver Disease. <b>2016</b> ,	3
79	Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. <b>2016</b> , 20, 351-64	9
78	Management of NAFLD: a stage-based approach. <b>2016</b> , 13, 196-205	195
77	Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis. <b>2016</b> , 61, 1387-97	25
76	Current and Emerging Therapies for Nonalcoholic Fatty Liver Disease. <b>2016</b> , 313-337	
75	Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children. <b>2016</b> , 20, 293-312	135
74	Beneficial effects of the Mediterranean spices and aromas on non-alcoholic fatty liver disease. <b>2017</b> , 61, 141-159	21
73	Reversal of liver fibrosis: From fiction to reality. <b>2017</b> , 31, 129-141	79
72	Pharmacological management of non-alcoholic fatty liver disease: Atorvastatin versus pentoxifylline. <b>2017</b> , 13, 2375-2381	24
71	Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis. <b>2017</b> , 3, CD011640	28
70	Effect of Pentoxifylline on Histological Activity and Fibrosis of Nonalcoholic Steatohepatitis Patients: A One Year Randomized Control Trial. <b>2017</b> , 5, 155-163	14

69	The pharmacological management of NAFLD in children and adolescents. <b>2017</b> , 10, 1225-1237	9
68	Disparities between research attention and burden in liver diseases: implications on uneven advances in pharmacological therapies in Europe and the USA. <b>2017</b> , 7, e013620	23
67	Pharmacotherapy of nonalcoholic steatohepatitis: Reflections on the existing evidence. <b>2017</b> , 18, 607-617	2
66	The therapeutic landscape of non-alcoholic steatohepatitis. <b>2017</b> , 37, 634-647	26
65	Therapies for non-alcoholic steatohepatitis. <b>2017</b> , 1, 214-220	1
64	Treatment options for alcoholic and non-alcoholic fatty liver disease: A review. <b>2017</b> , 23, 6549-6570	112
63	Glutathione disulfide sensitizes hepatocytes to TNF $\alpha$ -mediated cytotoxicity via IKK $\beta$ -S-glutathionylation: a potential mechanism underlying non-alcoholic fatty liver disease. <b>2018</b> , 50, 1-16	16
62	Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease. <b>2018</b> , 13, 321-350	234
61	WITHDRAWN: Nonalcoholic steatohepatitis therapies. <b>2018</b> ,	
60	The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups. <b>2018</b> , 33, 86-98	71
59	Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. <b>2018</b> , 22, 175-187	21
58	A systematic review of the present and future of non-alcoholic fatty liver disease. <b>2018</b> , 4, 165-174	30
57	Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. <b>2018</b> , 94, 556-565	11
56	Non-alcoholic fatty liver disease: controlling an emerging epidemic, challenges, and future directions. <b>2018</b> , 31, 288-295	37
55	Dietary and Pharmacological Treatment of Nonalcoholic Fatty Liver Disease. <b>2019</b> , 55,	22
54	Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment. <i>Diabetes and Metabolism Journal</i> , <b>2019</b> , 43, 127-143	5 23
53	A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis. <b>2019</b> , 11, 159-178	17
52	Treatments of nonalcoholic fatty liver disease in adults who have no other illness: A Review article. <b>2019</b> , 20, 189-197	1

51	Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients. <b>2019</b> , 114, 579-590	14
50	Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease. <b>2019</b> , 13, 193-204	39
49	Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis. <b>2019</b> , 17, 616-629.e26	53
48	Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. <b>2020</b> , 41,	56
47	Comparative effectiveness of phosphodiesterase 3, 4, and 5 inhibitors in amelioration of high-fat diet-induced nonalcoholic fatty liver in rats. <b>2020</b> , 34, 353-364	3
46	The molecular basis for current targets of NASH therapies. <b>2020</b> , 29, 151-161	8
45	Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. <b>2021</b> , 50, 101049	12
44	Novel targeted therapies for the management of liver fibrosis. <b>2020</b> , 25, 59-70	8
43	NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. <b>2020</b> , 69, 1691-1705	118
42	The Effect of Preoperative Pentoxifylline on Postoperative Pain and Development of Secondary Hyperalgesia in Patients Undergoing Laparoscopic Appendectomy: A Randomized, Double-Blind, Placebo-Controlled Trial Study. <b>2021</b> , 21, 18-25	
41	Fibrosis progression rate in a systematic review of placebo-treated nonalcoholic steatohepatitis. <b>2021</b> , 41, 982-995	5
40	The effect of acetylsalicylic acid and pentoxifylline in guinea pigs with non-alcoholic steatohepatitis. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2021</b> , 128, 583-593	3.1 2
39	Plant Fungal Pathogen Rhizoctonia Bataticola a Potential Source for Pharmaceutically Important Metabolites. <i>SSRN Electronic Journal</i> ,	1
38	Rhizoctonia bataticola: From plant pathogen to a potential source of pharmaceutically relevant metabolites. <i>Current Research in Green and Sustainable Chemistry</i> , <b>2021</b> , 4, 100171	4.1
37	Hepatic steatosis integrated approach: nutritional guidelines and joined nutraceutical administration. <i>Minerva Gastroenterologica E Dietologica</i> , <b>2020</b> , 66, 307-320	1.6
36	What proportion of people have a follow-up biopsy in randomized trials of treatments for non-alcoholic steatohepatitis?: A systematic review and meta-analysis. <i>PLoS ONE</i> , <b>2021</b> , 16, e0250385	3.7 1
35	Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. <i>Life Sciences</i> , <b>2021</b> , 271, 119220	6.8 11
34	Current Options and Future Directions for NAFLD and NASH Treatment. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3 12

33	Fatigue in Cirrhosis.. <i>Journal of Clinical and Experimental Hepatology</i> , <b>2022</b> , 12, 617-624	4.1	0
32	Physiological and Pathological Interactions Between Liver and Kidney. <b>2016</b> , 221-249		2
31	Pentoxifylline with metformin treatment improves biochemical parameters in patients with nonalcoholic steatohepatitis. <i>Journal of Medical Biochemistry</i> , <b>2020</b> , 39, 290-298	1.9	3
30	KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , <b>2013</b> , 19, 325-48	6.9	88
29	Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association. <i>Diabetes and Metabolism Journal</i> , <b>2020</b> , 44, 382-401	5	16
28	Role of pentoxifylline in non-alcoholic fatty liver disease in high-fat diet-induced obesity in mice. <i>World Journal of Hepatology</i> , <b>2015</b> , 7, 2551-8	3.4	7
27	Effect of Beta vulgaris Extract on Liver Enzymes in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial. <i>Hepatitis Monthly</i> , <b>2020</b> , 20,	1.8	2
26	Effects of Pentoxifylline on Non-Alcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial in Iran. <i>Hepatitis Monthly</i> , <b>2015</b> , 15, e32418	1.8	5
25	Occult Hepatitis C Infection Should Be More Noticed With New Treatment Strategies. <i>Hepatitis Monthly</i> , <b>2015</b> , 15, e33462	1.8	6
24	Analysis of Mechanistic Pathways in the Treatment of Non-Alcoholic Steatohepatitis. Evidence from a Bayesian Network Meta-Analysis.		0
23	Are the Protean Effects of Pentoxifylline in the Therapy of Diabetes and Its Complications Still Relevant?. <i>Diabetes Therapy</i> , <b>2021</b> , 12, 3025-3035	3.6	2
22	Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH). <b>2012</b> , 399-407		
21	Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. <i>Korean Journal of Medicine</i> , <b>2014</b> , 86, 425	0.5	1
20	Hepatic Fibrosis and Cirrhosis. 2070-2086		
19	What is the role of antifibrotic therapies in the current and future management of NAFLD?. 218-225		
18	Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes. <i>Contemporary Diabetes</i> , <b>2018</b> , 47-69	0	
17	TNF- $\beta$ signaling in non-alcoholic steatohepatitis and targeted therapies. <i>Journal of Genetics and Genomics</i> , <b>2021</b> ,	4	1
16	Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail. <i>Journal of Clinical and Translational Hepatology</i> , <b>2021</b> , 9, 40-50	5.2	4



15	Current and Potential Therapies Targeting Inflammation in NASH.. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 767314	5.7	2
14	Placebo Effect on Progression and Regression in Non-Alcoholic Steatohepatitis. Evidence from a Meta-Analysis.. <i>Hepatology</i> , <b>2022</b> ,	11.2	4
13	Nonalcoholic Fatty Liver Disease. <b>2022</b> , 443-450		
12	Meta-analysis: analysis of mechanistic pathways in the treatment of non-alcoholic steatohepatitis. Evidence from a Bayesian network meta-analysis.. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2022</b> ,	6.1	0
11	A Molecular Insight into the Role of Antioxidants in Nonalcoholic Fatty Liver Diseases. <i>Oxidative Medicine and Cellular Longevity</i> , <b>2022</b> , 2022, 1-15	6.7	0
10	Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: An overview and current perspectives. <i>Metabolism: Clinical and Experimental</i> , <b>2022</b> , 134, 155264	12.7	0
9	Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). <b>2022</b> , 7,		4
8	Disease state transition probabilities across the spectrum of NAFLD: A systematic review and meta-analysis of paired biopsy or imaging studies. <b>2022</b> ,		0
7	Placebo Adverse Events in Non-Alcoholic Steatohepatitis Clinical Trials. A Pooled Analysis of 2,944 Participants. <b>2022</b> , Publish Ahead of Print,		0
6	Side effect profile of pharmacologic therapies for liver fibrosis in nonalcoholic fatty liver disease: a systematic review and network meta-analysis. <b>2023</b> , 35, 1-14		1
5	Utility of Human Relevant Preclinical Animal Models in Navigating NAFLD to MAFLD Paradigm. <b>2022</b> , 23, 14762		0
4	Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies. <b>2023</b> , 15, 23		2
3	Lessons on Drug Development: A Literature Review of Challenges Faced in Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Trials. <b>2023</b> , 24, 158		0
2	Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review. <b>2023</b> , 59, 152165		0
1	Efficacy and Safety of Pentoxifylline on Patients with Non-Alcoholic Steatohepatitis; Randomized Controlled Trial.		0